Arkolith/Insider Trading/MNPR/Form 4

Robinson Chandler

Chief Executive Officer, DirectorMonopar Therapeutics (MNPR) · full profile →Form 4 · filed Jan 2, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 31, 2024Option exercise(M)5K——61K
Dec 31, 2024Tax withholding(F)2K$22.00$49K59K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 31, 2024Option exercise(M)5K—$025K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-25-000096) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML